#7 - Regeneron Pharmaceuticals (NASDAQ:REGN)
When your most well-known case study involves a former United States President, you have something to work with. That’s the case with the last stock on our list, Regeneron Pharmaceuticals (NASDAQ:REGN). The company made a big name for itself when former president Donald Trump was administered its therapeutic antibody cocktail treatment for Covid-19.
But that’s not the only reason, and maybe not the primary reason, that Regeneron is part of the ARK Genomic Revolution (NYSEMKT:ARKG) portfolio. The company’s Covid-19 therapeutic was not its first commercial success. And as Wood is betting it won’t be its last.
REGN stock has given up most of the gains it made in the last 12 months and is trading down approximately 3% in 2021. But some of that is coming from investors turning their eyes away from biotechs as vaccines are becoming more plentiful. However, that’s not the opinion of analysts who still rate the stock as a buy with a price target that gives REGN an upside of over 30%.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More - Current Price
- $738.00
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $1,099.55 (49.0% Upside)
Now that you’ve seen the stocks on this list, the choice about whether to invest in them is up to you. The ARK family of funds is actively managed by Wood. This means she is constantly buying and selling to achieve a market-beating return for her investors.
Her unapologetic high risk/high reward strategy may not be appropriate for every investor. And it shouldn’t make up a significant portion of our portfolio.
But if it’s right for you, now is the time to buy. Nobody can say for sure how long this rally in equities will last. But with interest rates remaining at historic lows and more stimulus hitting the economy, it’s likely that stocks will be the place to be for investors seeking capital growth.
These seven stocks are just a sampling of the funds that are part of the ARK fund family. However, if you’re an investor who believes in betting on the jockey as much if not more than the horse, you could do worse than following Cathie Wood’s lead.
More Investing Slideshows:
